Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease

• Main Authors: Maher Maha, Soloma Somaya
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2008-01-01
• Series: The Saudi Journal of Gastroenterology
• Subjects: Active state; inflammatory bowel disease; thrombophilic markers
• Online Access: http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2008;volume=14;issue=4;spage=192;epage=197;aulast=Maher

<b>Background/Aims:</b> Thromboembolic disease has been recognized as a complication of inflammatory bowel disease (IBD). The relative contributions of inherited or acquired thrombophilia and the inflammatory response to the mechanism of this tendency are unclear. Thrombotic events are more common in active disease although significant numbers also occur spontaneously. The aim of this study was to investigate common thrombophilic markers in patients with active IBD. <b> Methods:</b> Twenty-six patients with IBD who had active disease, and 40 sex- and age-matched non-IBD patients were recruited into the study. For all the subjects, complete blood counts, C-reactive protein levels, erythrocyte sedimentation rate, International normalized ratio, activated partial thromboplastin time, and levels of lupus anticoagulant, anticardiolipin antibodies (ACA IgG), proteins C and S, antithrombin-III (AT-III), and factor V were measured. <b> Results:</b> The International normalized ratio, activated partial thromboplastin time, and levels of proteins C and S were comparable between the two groups. However, antithrombin-III levels were significantly lower in the IBD group as compared with that in the healthy control group (<i> P</i> &lt; 0.001). ACA IgG was detected in one patient in the IBD group. Factor V Leiden mutation was present in 3.8&#x0025; of the patients in the IBD group, whereas the prevalence was 2.5&#x0025; in the control group. Significantly elevated platelet counts were observed in patients with active Crohn&#x2032;s disease compared with that in the control group (<i> P</i> &lt; 0.001), but they were not significantly increased in active ulcerative colitis (<i> P</i> = 0.231). <b> Conclusions:</b> The present study failed to establish a strong association between the common thrombophilic markers and the active clinical course of IBD, with the exception of high platelet counts and lower levels of AT-III in the IBD group as compared with those in the control group. All other parameters of thrombophilia were comparable between the two groups.